 Connection
Virginia Borges to Aromatase Inhibitors
This is a "connection" page, showing publications Virginia Borges has written about Aromatase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.437 |
|
|
|
-
Brown RJ, Sams S, Wolverton DE, Chong T, Borges VF, Rabinovitch RA, Murphy CD. Don't Be Fooled by DCIS. Oncology (Williston Park). 2017 07 15; 31(7):549-51, 560-1.
Score: 0.132
-
Ruddy KJ, DeSantis SD, Barry W, Guo H, Block CC, Borges V, Winer EP, Partridge AH. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clin Breast Cancer. 2014 Dec; 14(6):413-6.
Score: 0.106
-
Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat. 2008 Dec; 112(3):489-501.
Score: 0.069
-
Come SE, Borges VF. Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. Clin Breast Cancer. 2005 Apr; 6 Suppl 1:S15-22.
Score: 0.056
-
Wassermann J, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Come SE, Meyer ME, Partridge AH. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer. 2019 09 15; 125(18):3266-3274.
Score: 0.038
-
Stoen E, Kabos P, Borden KC, Brown RJ, Borges VF, Diamond JR. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer. Oncology (Williston Park). 2018 06; 32(6):298-302.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|